Changing  ||| S:0 E:9 ||| VBG
the  ||| S:9 E:13 ||| DT
paradigm  ||| S:13 E:22 ||| NN
in  ||| S:22 E:25 ||| IN
the  ||| S:25 E:29 ||| DT
treatment  ||| S:29 E:39 ||| NN
of  ||| S:39 E:42 ||| IN
platinum-sensitive  ||| S:42 E:61 ||| JJ
recurrent  ||| S:61 E:71 ||| JJ
ovarian  ||| S:71 E:79 ||| JJ
cancer ||| S:79 E:85 ||| NN
:  ||| S:85 E:87 ||| :
from  ||| S:87 E:92 ||| IN
platinum  ||| S:92 E:101 ||| NN
doublets  ||| S:101 E:110 ||| NN
to  ||| S:110 E:113 ||| TO
nonplatinum  ||| S:113 E:125 ||| VB
doublets  ||| S:125 E:134 ||| NNS
and  ||| S:134 E:138 ||| CC
adding  ||| S:138 E:145 ||| VBG
antiangiogenesis  ||| S:145 E:162 ||| NNS
compounds  ||| S:162 E:172 ||| VBP
The  ||| S:172 E:176 ||| DT
optimal  ||| S:176 E:184 ||| JJ
treatment  ||| S:184 E:194 ||| NN
for  ||| S:194 E:198 ||| IN
women  ||| S:198 E:204 ||| NNS
with  ||| S:204 E:209 ||| IN
recurrent  ||| S:209 E:219 ||| JJ
epithelial  ||| S:219 E:230 ||| JJ
ovarian  ||| S:230 E:238 ||| JJ
cancer  ||| S:238 E:245 ||| NN
is  ||| S:245 E:248 ||| VBZ
evolving ||| S:248 E:256 ||| VBG
.  ||| S:256 E:258 ||| .
The  ||| S:258 E:262 ||| DT
objective  ||| S:262 E:272 ||| NN
of  ||| S:272 E:275 ||| IN
this  ||| S:275 E:280 ||| DT
review  ||| S:280 E:287 ||| NN
is  ||| S:287 E:290 ||| VBZ
to  ||| S:290 E:293 ||| TO
outline  ||| S:293 E:301 ||| VB
the  ||| S:301 E:305 ||| DT
transition  ||| S:305 E:316 ||| NN
away  ||| S:316 E:321 ||| RB
from  ||| S:321 E:326 ||| IN
platinum  ||| S:326 E:335 ||| NN
doublets  ||| S:335 E:344 ||| NN
toward  ||| S:344 E:351 ||| IN
nonplatinum  ||| S:351 E:363 ||| JJ
combinations  ||| S:363 E:376 ||| NNS
and  ||| S:376 E:380 ||| CC
review  ||| S:380 E:387 ||| VB
emerging  ||| S:387 E:396 ||| VBG
data  ||| S:396 E:401 ||| NNS
on  ||| S:401 E:404 ||| IN
antiangiogenesis  ||| S:404 E:421 ||| JJ
therapy  ||| S:421 E:429 ||| NN
in  ||| S:429 E:432 ||| IN
this  ||| S:432 E:437 ||| DT
setting ||| S:437 E:444 ||| NN
.  ||| S:444 E:446 ||| .
Recently  ||| S:446 E:455 ||| RB
published  ||| S:455 E:465 ||| VBN
and  ||| S:465 E:469 ||| CC
presented  ||| S:469 E:479 ||| VBN
data  ||| S:479 E:484 ||| NNS
as  ||| S:484 E:487 ||| IN
well  ||| S:487 E:492 ||| RB
as  ||| S:492 E:495 ||| IN
ongoing  ||| S:495 E:503 ||| JJ
clinical  ||| S:503 E:512 ||| JJ
trials  ||| S:512 E:519 ||| NNS
are  ||| S:519 E:523 ||| VBP
discussed ||| S:523 E:532 ||| VBN
.  ||| S:532 E:534 ||| .
Current  ||| S:534 E:542 ||| JJ
clinical  ||| S:542 E:551 ||| JJ
practice  ||| S:551 E:560 ||| NN
largely  ||| S:560 E:568 ||| RB
harmonizes  ||| S:568 E:579 ||| VBN
with  ||| S:579 E:584 ||| IN
a  ||| S:584 E:586 ||| DT
paradigm  ||| S:586 E:595 ||| NN
that  ||| S:595 E:600 ||| WDT
outlines  ||| S:600 E:609 ||| VBZ
a  ||| S:609 E:611 ||| DT
treatment  ||| S:611 E:621 ||| NN
algorithm  ||| S:621 E:631 ||| NN
for  ||| S:631 E:635 ||| IN
recurrent  ||| S:635 E:645 ||| JJ
ovarian  ||| S:645 E:653 ||| JJ
cancer  ||| S:653 E:660 ||| NN
based  ||| S:660 E:666 ||| VBN
on  ||| S:666 E:669 ||| IN
the  ||| S:669 E:673 ||| DT
duration  ||| S:673 E:682 ||| NN
of  ||| S:682 E:685 ||| IN
platinum-free  ||| S:685 E:699 ||| JJ
exposure ||| S:699 E:707 ||| NN
.  ||| S:707 E:709 ||| .
In  ||| S:709 E:712 ||| IN
this  ||| S:712 E:717 ||| DT
model ||| S:717 E:722 ||| NN
,  ||| S:722 E:724 ||| ,
patients  ||| S:724 E:733 ||| NNS
whose  ||| S:733 E:739 ||| WP$
penultimate  ||| S:739 E:751 ||| JJ
platinum  ||| S:751 E:760 ||| NN
compound  ||| S:760 E:769 ||| NN
exposure  ||| S:769 E:778 ||| NN
( ||| S:778 E:779 ||| -LRB-
platinum-free  ||| S:779 E:793 ||| JJ
interval  ||| S:793 E:802 ||| NNS
[ ||| S:802 E:803 ||| -LRB-
PFI ||| S:803 E:806 ||| NNP
] ||| S:806 E:807 ||| -RRB-
)  ||| S:807 E:809 ||| -RRB-
is  ||| S:809 E:812 ||| VBZ
longer  ||| S:812 E:819 ||| RB
than  ||| S:819 E:824 ||| IN
6  ||| S:824 E:826 ||| CD
months  ||| S:826 E:833 ||| NNS
are  ||| S:833 E:837 ||| VBP
generally  ||| S:837 E:847 ||| RB
offered  ||| S:847 E:855 ||| VBN
a  ||| S:855 E:857 ||| DT
platinum  ||| S:857 E:866 ||| NN
agent  ||| S:866 E:872 ||| NN
or  ||| S:872 E:875 ||| CC
a  ||| S:875 E:877 ||| DT
platinum-containing  ||| S:877 E:897 ||| JJ
doublet ||| S:897 E:904 ||| NN
;  ||| S:904 E:906 ||| :
those  ||| S:906 E:912 ||| DT
with  ||| S:912 E:917 ||| IN
a  ||| S:917 E:919 ||| DT
shorter  ||| S:919 E:927 ||| JJR
interval  ||| S:927 E:936 ||| NNS
are  ||| S:936 E:940 ||| VBP
usually  ||| S:940 E:948 ||| RB
treated  ||| S:948 E:956 ||| VBN
with  ||| S:956 E:961 ||| IN
a  ||| S:961 E:963 ||| DT
single  ||| S:963 E:970 ||| JJ
nonplatinum  ||| S:970 E:982 ||| JJ
agent ||| S:982 E:987 ||| NN
.  ||| S:987 E:989 ||| .
This  ||| S:989 E:994 ||| DT
is  ||| S:994 E:997 ||| VBZ
based  ||| S:997 E:1003 ||| VBN
on  ||| S:1003 E:1006 ||| IN
the  ||| S:1006 E:1010 ||| DT
simple  ||| S:1010 E:1017 ||| JJ
contention  ||| S:1017 E:1028 ||| NN
that  ||| S:1028 E:1033 ||| IN
better  ||| S:1033 E:1040 ||| JJR
clinical  ||| S:1040 E:1049 ||| JJ
outcomes  ||| S:1049 E:1058 ||| NNS
will  ||| S:1058 E:1063 ||| MD
be  ||| S:1063 E:1066 ||| VB
realized  ||| S:1066 E:1075 ||| VBN
with  ||| S:1075 E:1080 ||| IN
platinum  ||| S:1080 E:1089 ||| NN
in  ||| S:1089 E:1092 ||| IN
those  ||| S:1092 E:1098 ||| DT
deemed  ||| S:1098 E:1105 ||| JJ
platinum  ||| S:1105 E:1114 ||| NN
sensitive  ||| S:1114 E:1124 ||| JJ
( ||| S:1124 E:1125 ||| -LRB-
PFI  ||| S:1125 E:1129 ||| NNP
> ||| S:1129 E:1130 ||| CD
6  ||| S:1130 E:1132 ||| CD
months ||| S:1132 E:1138 ||| NNS
) ||| S:1138 E:1139 ||| -RRB-
.  ||| S:1139 E:1141 ||| .
However ||| S:1141 E:1148 ||| RB
,  ||| S:1148 E:1150 ||| ,
it  ||| S:1150 E:1153 ||| PRP
is  ||| S:1153 E:1156 ||| VBZ
becoming  ||| S:1156 E:1165 ||| VBG
clear  ||| S:1165 E:1171 ||| JJ
from  ||| S:1171 E:1176 ||| IN
various  ||| S:1176 E:1184 ||| JJ
phase  ||| S:1184 E:1190 ||| NN
II  ||| S:1190 E:1193 ||| NNP
and  ||| S:1193 E:1197 ||| CC
phase  ||| S:1197 E:1203 ||| NN
III  ||| S:1203 E:1207 ||| NNP
clinical  ||| S:1207 E:1216 ||| JJ
studies  ||| S:1216 E:1224 ||| NNS
that  ||| S:1224 E:1229 ||| IN
the  ||| S:1229 E:1233 ||| DT
performance  ||| S:1233 E:1245 ||| NN
of  ||| S:1245 E:1248 ||| IN
many  ||| S:1248 E:1253 ||| JJ
nonplatinum  ||| S:1253 E:1265 ||| JJ
chemotherapeutic  ||| S:1265 E:1282 ||| JJ
agents  ||| S:1282 E:1289 ||| NNS
is  ||| S:1289 E:1292 ||| VBZ
also  ||| S:1292 E:1297 ||| RB
influenced  ||| S:1297 E:1308 ||| VBN
by  ||| S:1308 E:1311 ||| IN
this  ||| S:1311 E:1316 ||| DT
parameter  ||| S:1316 E:1326 ||| NN
( ||| S:1326 E:1327 ||| -LRB-
PFI ||| S:1327 E:1330 ||| NNP
) ||| S:1330 E:1331 ||| -RRB-
.  ||| S:1331 E:1333 ||| .
Indeed ||| S:1333 E:1339 ||| RB
,  ||| S:1339 E:1341 ||| ,
although  ||| S:1341 E:1350 ||| IN
definitive  ||| S:1350 E:1361 ||| JJ
comparisons  ||| S:1361 E:1373 ||| NNS
of  ||| S:1373 E:1376 ||| IN
nonplatinum  ||| S:1376 E:1388 ||| JJ
drugs  ||| S:1388 E:1394 ||| NNS
to  ||| S:1394 E:1397 ||| TO
novel  ||| S:1397 E:1403 ||| VB
cytotoxic  ||| S:1403 E:1413 ||| JJ
agents  ||| S:1413 E:1420 ||| NNS
are  ||| S:1420 E:1424 ||| VBP
lacking ||| S:1424 E:1431 ||| VBG
,  ||| S:1431 E:1433 ||| ,
the  ||| S:1433 E:1437 ||| DT
clinical  ||| S:1437 E:1446 ||| JJ
activity  ||| S:1446 E:1455 ||| NN
of  ||| S:1455 E:1458 ||| IN
these  ||| S:1458 E:1464 ||| DT
compounds  ||| S:1464 E:1474 ||| NN
might  ||| S:1474 E:1480 ||| MD
approach  ||| S:1480 E:1489 ||| VB
or  ||| S:1489 E:1492 ||| CC
exceed  ||| S:1492 E:1499 ||| VB
that  ||| S:1499 E:1504 ||| IN
of  ||| S:1504 E:1507 ||| IN
platinum  ||| S:1507 E:1516 ||| NN
agents ||| S:1516 E:1522 ||| NNS
.  ||| S:1522 E:1524 ||| .
Although  ||| S:1524 E:1533 ||| IN
recognized  ||| S:1533 E:1544 ||| VBN
by  ||| S:1544 E:1547 ||| IN
clinicians ||| S:1547 E:1557 ||| NN
,  ||| S:1557 E:1559 ||| ,
the  ||| S:1559 E:1563 ||| DT
dichotomy  ||| S:1563 E:1573 ||| NN
that  ||| S:1573 E:1578 ||| WDT
determines  ||| S:1578 E:1589 ||| VBZ
therapy  ||| S:1589 E:1597 ||| VBN
based  ||| S:1597 E:1603 ||| VBN
on  ||| S:1603 E:1606 ||| IN
PFI  ||| S:1606 E:1610 ||| NNP
has  ||| S:1610 E:1614 ||| VBZ
not  ||| S:1614 E:1618 ||| RB
been  ||| S:1618 E:1623 ||| VBN
formally  ||| S:1623 E:1632 ||| RB
accepted  ||| S:1632 E:1641 ||| VBN
by  ||| S:1641 E:1644 ||| IN
the  ||| S:1644 E:1648 ||| DT
US  ||| S:1648 E:1651 ||| NNP
Food  ||| S:1651 E:1656 ||| NNP
and  ||| S:1656 E:1660 ||| CC
Drug  ||| S:1660 E:1665 ||| NNP
Administration  ||| S:1665 E:1680 ||| NNP
in  ||| S:1680 E:1683 ||| IN
all  ||| S:1683 E:1687 ||| DT
cases  ||| S:1687 E:1693 ||| NNS
of  ||| S:1693 E:1696 ||| IN
drug  ||| S:1696 E:1701 ||| NN
labeling ||| S:1701 E:1709 ||| NN
.  ||| S:1709 E:1711 ||| .
For  ||| S:1711 E:1715 ||| IN
instance ||| S:1715 E:1723 ||| NN
,  ||| S:1723 E:1725 ||| ,
whereas  ||| S:1725 E:1733 ||| IN
the  ||| S:1733 E:1737 ||| DT
combination  ||| S:1737 E:1749 ||| NN
of  ||| S:1749 E:1752 ||| IN
gemcitabine  ||| S:1752 E:1764 ||| NN
and  ||| S:1764 E:1768 ||| CC
carboplatin  ||| S:1768 E:1780 ||| NN
is  ||| S:1780 E:1783 ||| VBZ
now  ||| S:1783 E:1787 ||| RB
approved  ||| S:1787 E:1796 ||| VBN
for  ||| S:1796 E:1800 ||| IN
patients  ||| S:1800 E:1809 ||| NNS
with  ||| S:1809 E:1814 ||| IN
platinum-sensitive  ||| S:1814 E:1833 ||| JJ
recurrent  ||| S:1833 E:1843 ||| JJ
ovarian  ||| S:1843 E:1851 ||| JJ
cancer ||| S:1851 E:1857 ||| NN
,  ||| S:1857 E:1859 ||| ,
traditionally  ||| S:1859 E:1873 ||| RB
used  ||| S:1873 E:1878 ||| VBN
platinum-resistant  ||| S:1878 E:1897 ||| JJ
( ||| S:1897 E:1898 ||| -LRB-
PFI  ||| S:1898 E:1902 ||| NNP
< ||| S:1902 E:1903 ||| SYM
6  ||| S:1903 E:1905 ||| CD
months ||| S:1905 E:1911 ||| NNS
)  ||| S:1911 E:1913 ||| -RRB-
agents  ||| S:1913 E:1920 ||| NNS
such  ||| S:1920 E:1925 ||| JJ
as  ||| S:1925 E:1928 ||| IN
topotecan  ||| S:1928 E:1938 ||| NN
and  ||| S:1938 E:1942 ||| CC
pegylated  ||| S:1942 E:1952 ||| JJ
liposomal  ||| S:1952 E:1962 ||| JJ
doxorubicin  ||| S:1962 E:1974 ||| NNS
are  ||| S:1974 E:1978 ||| VBP
also  ||| S:1978 E:1983 ||| RB
approved  ||| S:1983 E:1992 ||| VBN
by  ||| S:1992 E:1995 ||| IN
the  ||| S:1995 E:1999 ||| DT
US  ||| S:1999 E:2002 ||| NNP
Food  ||| S:2002 E:2007 ||| NNP
and  ||| S:2007 E:2011 ||| CC
Drug  ||| S:2011 E:2016 ||| NNP
Administration  ||| S:2016 E:2031 ||| NNP
as  ||| S:2031 E:2034 ||| IN
single  ||| S:2034 E:2041 ||| JJ
agents  ||| S:2041 E:2048 ||| NNS
in  ||| S:2048 E:2051 ||| IN
platinum-sensitive  ||| S:2051 E:2070 ||| JJ
patients ||| S:2070 E:2078 ||| NNS
.  ||| S:2078 E:2080 ||| .
Furthermore ||| S:2080 E:2091 ||| RB
,  ||| S:2091 E:2093 ||| ,
the  ||| S:2093 E:2097 ||| DT
nonplatinum  ||| S:2097 E:2109 ||| FW
doublet  ||| S:2109 E:2117 ||| FW
pegylated  ||| S:2117 E:2127 ||| FW
liposomal  ||| S:2127 E:2137 ||| FW
doxorubicin  ||| S:2137 E:2149 ||| FW
and  ||| S:2149 E:2153 ||| CC
trabectedin  ||| S:2153 E:2165 ||| NN
has  ||| S:2165 E:2169 ||| VBZ
recently  ||| S:2169 E:2178 ||| RB
documented  ||| S:2178 E:2189 ||| VBN
comparable  ||| S:2189 E:2200 ||| JJ
activity  ||| S:2200 E:2209 ||| NN
to  ||| S:2209 E:2212 ||| TO
platinum  ||| S:2212 E:2221 ||| NN
combinations  ||| S:2221 E:2234 ||| NNS
among  ||| S:2234 E:2240 ||| IN
patients  ||| S:2240 E:2249 ||| NNS
with  ||| S:2249 E:2254 ||| IN
a  ||| S:2254 E:2256 ||| DT
PFI  ||| S:2256 E:2260 ||| NNP
of  ||| S:2260 E:2263 ||| IN
longer  ||| S:2263 E:2270 ||| JJR
than  ||| S:2270 E:2275 ||| IN
6  ||| S:2275 E:2277 ||| CD
months ||| S:2277 E:2283 ||| NNS
.  ||| S:2283 E:2285 ||| .
To  ||| S:2285 E:2288 ||| TO
that  ||| S:2288 E:2293 ||| DT
end ||| S:2293 E:2296 ||| NN
,  ||| S:2296 E:2298 ||| ,
the  ||| S:2298 E:2302 ||| DT
most  ||| S:2302 E:2307 ||| RBS
prolific  ||| S:2307 E:2316 ||| JJ
developmental  ||| S:2316 E:2330 ||| JJ
therapeutics  ||| S:2330 E:2343 ||| JJ
arena  ||| S:2343 E:2349 ||| NN
in  ||| S:2349 E:2352 ||| IN
ovarian  ||| S:2352 E:2360 ||| JJ
cancer  ||| S:2360 E:2367 ||| NN
is  ||| S:2367 E:2370 ||| VBZ
biologically  ||| S:2370 E:2383 ||| VBN
targeted  ||| S:2383 E:2392 ||| VBN
therapy ||| S:2392 E:2399 ||| NN
,  ||| S:2399 E:2401 ||| ,
particularly  ||| S:2401 E:2414 ||| RB
angiogenesis  ||| S:2414 E:2427 ||| JJ
inhibitors ||| S:2427 E:2437 ||| NN
.  ||| S:2437 E:2439 ||| .
Although  ||| S:2439 E:2448 ||| IN
it  ||| S:2448 E:2451 ||| PRP
is  ||| S:2451 E:2454 ||| VBZ
unknown  ||| S:2454 E:2462 ||| VBN
if  ||| S:2462 E:2465 ||| IN
the  ||| S:2465 E:2469 ||| DT
clinical  ||| S:2469 E:2478 ||| JJ
activity  ||| S:2478 E:2487 ||| NN
from  ||| S:2487 E:2492 ||| IN
these  ||| S:2492 E:2498 ||| DT
new  ||| S:2498 E:2502 ||| JJ
agents  ||| S:2502 E:2509 ||| NNS
will  ||| S:2509 E:2514 ||| MD
respect  ||| S:2514 E:2522 ||| VB
the  ||| S:2522 E:2526 ||| DT
chemotherapy-sensitive  ||| S:2526 E:2549 ||| JJ
dichotomy ||| S:2549 E:2558 ||| NN
,  ||| S:2558 E:2560 ||| ,
it  ||| S:2560 E:2563 ||| PRP
is  ||| S:2563 E:2566 ||| VBZ
clear  ||| S:2566 E:2572 ||| JJ
that  ||| S:2572 E:2577 ||| IN
they  ||| S:2577 E:2582 ||| PRP
have  ||| S:2582 E:2587 ||| VBP
the  ||| S:2587 E:2591 ||| DT
potential  ||| S:2591 E:2601 ||| JJ
to  ||| S:2601 E:2604 ||| TO
augment  ||| S:2604 E:2612 ||| VB
efficacy ||| S:2612 E:2620 ||| NNS
,  ||| S:2620 E:2622 ||| ,
possibly  ||| S:2622 E:2631 ||| RB
in  ||| S:2631 E:2634 ||| IN
both  ||| S:2634 E:2639 ||| DT
traditionally  ||| S:2639 E:2653 ||| JJ
chemosensitive  ||| S:2653 E:2668 ||| NN
and  ||| S:2668 E:2672 ||| CC
chemoresistant  ||| S:2672 E:2687 ||| JJ
phenotypes ||| S:2687 E:2697 ||| NN
.  ||| S:2697 E:2699 ||| .
The  ||| S:2699 E:2703 ||| DT
term  ||| S:2703 E:2708 ||| NN
platinum  ||| S:2708 E:2717 ||| NN
sensitive  ||| S:2717 E:2727 ||| NNS
should  ||| S:2727 E:2734 ||| MD
probably  ||| S:2734 E:2743 ||| RB
be  ||| S:2743 E:2746 ||| VB
replaced  ||| S:2746 E:2755 ||| VBN
by  ||| S:2755 E:2758 ||| IN
chemotherapy  ||| S:2758 E:2771 ||| JJ
sensitive ||| S:2771 E:2780 ||| JJ
,  ||| S:2780 E:2782 ||| ,
particularly  ||| S:2782 E:2795 ||| RB
as  ||| S:2795 E:2798 ||| IN
new  ||| S:2798 E:2802 ||| JJ
nonplatinum  ||| S:2802 E:2814 ||| JJ
agents  ||| S:2814 E:2821 ||| NNS
and  ||| S:2821 E:2825 ||| CC
combinations  ||| S:2825 E:2838 ||| NNS
are  ||| S:2838 E:2842 ||| VBP
identified  ||| S:2842 E:2853 ||| VBN
as  ||| S:2853 E:2856 ||| IN
active  ||| S:2856 E:2863 ||| JJ
in  ||| S:2863 E:2866 ||| IN
this  ||| S:2866 E:2871 ||| DT
setting ||| S:2871 E:2878 ||| NN
.  ||| S:2878 E:2880 ||| .
Nonplatinum  ||| S:2880 E:2892 ||| JJ
doublets  ||| S:2892 E:2901 ||| NNS
are  ||| S:2901 E:2905 ||| VBP
effective  ||| S:2905 E:2915 ||| JJ
in  ||| S:2915 E:2918 ||| IN
treating  ||| S:2918 E:2927 ||| VBG
platinum-sensitive  ||| S:2927 E:2946 ||| JJ
recurrent  ||| S:2946 E:2956 ||| JJ
disease ||| S:2956 E:2963 ||| NN
,  ||| S:2963 E:2965 ||| ,
and  ||| S:2965 E:2969 ||| CC
adding  ||| S:2969 E:2976 ||| VBG
antiangiogenesis  ||| S:2976 E:2993 ||| JJ
agents  ||| S:2993 E:3000 ||| NNS
to  ||| S:3000 E:3003 ||| TO
these  ||| S:3003 E:3009 ||| DT
combinations  ||| S:3009 E:3022 ||| NN
is  ||| S:3022 E:3025 ||| VBZ
a  ||| S:3025 E:3027 ||| DT
research  ||| S:3027 E:3036 ||| NN
priority ||| S:3036 E:3044 ||| NN
.  ||| S:3044 E:3046 ||| .
